Smith & Nephew Plc
22 May 2002
22 May 2002
Smith & Nephew analyst visit
Smith & Nephew, the global advanced medical devices group, today began a one day
visit of analysts and institutional investors to the headquarters of its
endoscopy business in Andover, Mass. During the visit, guests have the
opportunity to meet senior management and receive presentations on products and
Endoscopy's research and development programme.
The visit is hosted by Chief Executive Chris O'Donnell, who told the visitors:
'Our endoscopy business is already the world leader in minimally invasive
surgery for joints. We intend to maintain our strength in this area, and also
use it as a platform to expand into other carefully selected and
procedure-specific areas where our knowledge of minimally invasive techniques
can benefit patients, surgeons and healthcare providers.
'We intend to grow this business organically and by acquisition, and I am
pleased to report that Endoscopy's recent acquisition of Oratec is living up to
our expectations, with integration proceeding on schedule.'
Enquiries:
Margaret Stewart, Group Director, Corporate Affairs Tel: +44 (0) 20 7401 7646
Smith & Nephew plc
David Yates Tel: +44 (0) 20 7831 3113
Financial Dynamics
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.